Table 3.
ACG and AGA Guideline Recommendations for Currently Available FDA-Approved Agents With Indications for the Treatment of IBS-C
| Agent | ACG recommendation10 | AGA recommendation9 |
|---|---|---|
| Lubiprostone | Chloride channel activators are recommended to treat global IBS-C symptoms (strong recommendation) | Suggests using in patients with IBS-C (conditional suggestion) |
| Linaclotide | GC-C agonists are recommended to treat global IBS-C symptoms (strong recommendation) | Suggests using in patients with IBS-C (strong recommendation) |
| Plecanatide | Suggests using in patients with IBS-C (conditional suggestion) | |
| Tenapanor | Not reviewed | Suggests using in patients with IBS-C (conditional suggestion) |
ACG, American College of Gastroenterology; AGA, American Gastroenterological Association; FDA, US Food and Drug Administration; GC-C, guanylate cyclase-C; IBS-C, irritable bowel syndrome with constipation.